USFDA grants VAI classification to Dr Reddy’s R&D centre – ET HealthWorld | Pharma


Hyderabad: Dr Reddy’s Laboratories on Monday mentioned the US health regulator has granted Voluntary Motion Indicated (VAI) classification to its Hyderabad-based R&D centre put up inspection. A VAI classification means objectionable circumstances or practices had been discovered however the company was not ready to take or suggest any administrative or regulatory motion.

The drug main mentioned its R&D centre — Integrated Product Development Organisation — in Bachupally, Hyderabad, underwent a Good Manufacturing Practice and pre-approval inspection by the US Food and Drug Administration (USFDA) in December 2023.

The USFDA has now categorised that inspection as VAI, it added.

Final week, the drug main mentioned the USFDA has issued VAI standing to FTO-3, its largest formulations manufacturing plant in Bachupally and concluded the inspection as closed.

Shares of the drugmaker on Monday ended 2.56 per cent up at Rs 6,309.95 apiece on the BSE.

  • Printed On Feb 12, 2024 at 06:01 PM IST

Be part of the neighborhood of 2M+ trade professionals

Subscribe to our e-newsletter to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles

Scan to obtain App

Source link

Previous article​Excellent Valentine’s Day reward for e book lovers
Next articleMithila Palkar to make her Tamil debut alongside Vishnu Vishal’s brother Rudra in ‘Oho Enthan Child’


Please enter your comment!
Please enter your name here